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Purpose/Objective: The purpose of this study is to evaluate the 
clinical efficacy of High precision IMRT combined with neoadjuvant & 
concurrent MAB for intermediate- & high-risk prostate cancer 
patients. 
Materials and Methods: Between Sep 2000 and Dec 2007, 200 
localized prostate carcinomas (T1-T3, N0M0) were treated with 
neoadjuvant (3-6 months) and concurrent (2months) hormonal 
therapy. Maximum androgen blockade (MAB) was used as hormonal 
therapy. There were 120 high-risk and 80 intermediate-risk group 
patients. Initial PSA level was ranging 4.0-142 ng/ml (median: 
12.5ng/ml) and Gleason score was ranging 5-10 (median: 7). Median 
follow-up duration is 6.04Y (range: 0.7-11.6Y). IMRT was delivered 
with SMLC-IMRT technique using a 2Gy/fraction to a total dose of 
76Gy. GTV was defined as prostate and CTV was defined as GTV+ 
seminal vesicles. PTV margin was 7mm around the CTV except for 
posterior direction. Posterior margin was 5-6mm. We used 3-gold 
markers implanted to the prostate for localization. After radiation 
therapy, no further hormonal therapy was used until PSA failure. The 
PSA failure definition was done according to Phoenix criteria. The 
follow-up interval was every 3months. We evaluate the PSA failure 
free survival rate (PFFS), Overall survival rate (OS) and acute and late 
sequelae by CTCAE (version4.0). 
Results: The PFFS at 5-/ 7-years of intermediate- and high-risk group 
were 96.1%/96.1%, 85.2%/80.5%, respectively. The OS at 5-/7-years of 
each group were 98.7%/97.4%, 95.8%/95.8%, respectively. Although 
the PFFS for high risk group was good, the PFFS for special group 
(>=T3&PSA>=20&GS>=8) was only 65%. The cause of death was another 
cancer (lung, esophagus, stomach). Acute Grade 1/2 genitourinally 
and gastrointesitinal sequelae was observed in 66.0%/6.0%, 2.5%/1.0%, 
respectively. No grade 3 acute sequelae was observed. Late Grade 1 
urogenital and gastrointestinal sequelae were observed in 24.1%, 
9.1%, respectively. Grade3 urethral stricture was observed in 2 
patients. All of them recovered after bougie. No grade 2 or higher 
rectal complication was observed. 
Conclusions: According to our results, short course (3-6months) 
neoadjuvant and concurrent (2 months) MAB with 76Gy irradiation 
with IMRT/IGRT technique would be effective for intermediate& high 
risk prostate cancer patients at 7 years. For the special group 
(>=T3&PSA>=20&GS>=8), another treatment option might be 
necessary.  
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Purpose/Objective: Feasibility and dosimetric comparison of the 
sequential and simultaneous integrated boost IMRT delivery 
techniques on target coverage and normal-tissue sparing. A sequential 
two-phase process,initial and boost irradiation, is the common 
practice for the radiotherapy management of high-risk prostate 
cancer. In this work, we explore the feasibility of using intensity 
modulated radiation therapy (IMRT) simultaneous integrated boost 
(SIB), a single-phase process, to simultaneously deliver high dose to 
the prostate and lower dose to the pelvic nodes, in our setup. 
Materials and Methods: The study included 25 patients of 
intermediate-high risk carcinoma prostate. Patients were immobilized 
with thermoplastic cast in supine position. Target volumes i.e. PTV 
P+SV (Prostate and Seminal vesicles), PTV LN and organs at risk were 
delineated as per the RTOG census guidelines. On Eclipse version 6.5, 
two plans were generated i.e. sequential 3DCRT (4 field box 
technique) followed by seven field IMRT boost & seven field SIB-IMRT. 
Prescribed dose to PTV P+SV was 74 Gy/37#/7.2 wks for sequential 
plan & 74 Gy/27#/5.2 wks for SIB IMRT. Dose to PTV-LN was 50 
Gy/25#/5wks for SEQ IMRT and 54Gy/27#/5.5wks for SIB-IMRT plan. 
Plan comparison was done using dose volume histogram (DVH) in terms 
of target coverage index (CI=target volume covered by prescription 
dose/target volume) and heterogeneity index (HI=D5/D95). For OAR 
maximum and mean doses and volume of OAR receiving different 
doses. 
Results: Results of SEQ-IMRT and SIB-IMRT are summarized in table1. 
SIB-IMRT delivered a higher EQD2 (87 vs 74Gy) to PTV P+SV. Target 
coverage was better with SIB-IMRT both in terms of conformity & 
homogeneity indices. SIB IMRT reduced dose to critical organs at risk 
in terms of mean and max dose. Analysis of DVH parameters (Rectum 
V75, V65, V50, Bladder V75, V65 and Bowel V45) revealed better 
sparing of OARs with SIB-IMRT. 
 
 SIB-IMRT SEQ-IMRT  PTV P+SV Max.(cGy)  8139.40±60.00 8204.25±122.65 
PTV P+SV Mean (cGy) 7771.42±17.88 7609.95±78.35 
PTV P+SV CI 0.9843±0.0127 0.9085±0.05 
PTV P+SV HI 1.0555±0.0008 1.0743±0.0011 
PTV LN Max. (cGy) 7921.87±30.3 7425.37±60.93 
PTV LN Mean(cGy) 5864.47±71.4 5901.97±38.53 
PTV LN CI 0.98261±0.0172 0.99195±0.0061 
PTV LN HI 1.4432±0.0272 1.1261±0.204 
BLADDER Max. (cGy) 7721.97±93.5 7903.87±40.63 
BLADDER Mean(cGy) 5368.5±299.6 6409.7±551.5 
RECTUM Max. (cGy) 7640.7±95.7 7804.15±59.05 
RECTUM Mean(cGy) 5599.25±204.55 6473.00±59.05 
BOWEL Max. (cGy) 5951.45±369.45 5699.47±183.13 
BOWEL Mean(cGy) 2421.45±215.65 2827.42±133.78 
Bladder V75 5.15±5.27 23.99±18.69 
Bladder V65 28.50±6.32 60.31±16.25 
Rectum V75 5.39±13.36 17.47±3.85 
Rectum V65 31.39±13.05 53.85±30.6 
Rectum V50 65.01±14.36 89.36±3.3 
Bowel V45 13.86±4.68 24.4±11.54 
 
Conclusions: Delivery of SIB IMRT was safe and feasible with regard to 
target coverage. SIB-IMRT was superior to sequential IMRT in 
delivering reduced doses to adjoining organs at risk. A further study in 
large volume exploring the role of SIB IMRT with its potential 
dosimetric and radiobiological advantages in carcinoma prostate is 
warranted in our setup. 
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Purpose/Objective: The diagnosis of prostate cancer (PCa) may cause 
psychological distress. The Memorial Anxiety Scale for Prostate Cancer 
(MAX-PC) (Roth A., 2006) is a self-report questionnaire that was 
developed to assess PCa-related anxiety. MAX-PC has proven to be a 
valid and reliable tool which can be translated and adapted for use in 
non-English speaking populations. The aim of this study was to present 
the procedures for cultural adaptation for the Italian population 
together with the preliminary results for psychometric properties. 
Materials and Methods: The study sample was composed of patients 
(pts) diagnosed with PCa who either were on Active Surveillance (AS) 
or underwent radical radiotherapy (RT). Pts filled out MAX-PC before 
undergoing RT or entering the AS protocol. The questionnaire consists 
of 18 items divided into 3 subscales measuring general PCa anxiety, 
anxiety related to prostate specific antigen (PSA) levels, and fear of 
recurrence. The original English version was translated in Italian by 
two independent researchers; the back translation into English was 
performed by two native English-speaking translators. Back 
translations were discussed and re-translated into Italian to obtain a 
final version. Psychometric analyses were performed to obtain 
reliability indexes. Specifically, a) descriptive analyses to detect 
floor/ceiling effect, b) Cronbach's alpha coefficients (α) to estimate 
the internal consistency of the total MAX-PC and the three subscales, 
c) item to total correlation analyses to assess subscales internal 
consistency.  
Results: One hundred and thirty pts (118 AS – low risk, localized PCa; 
12 RT – low to intermediate risk) filled in MAX-PC. Table 1 reports 
